Global health technology leader Royal Philips and continuous health monitoring company BioIntelliSense will receive nearly $2.8 million from the US Department of Defense (DoD) to validate BioIntelliSense’s FDA-cleared BioSticker wearable device for early COVID-19 symptom detection.
CU Anschutz
Fitzsimons Building
13001 East 17th Place
Aurora, CO 80045